TD Cowen lowered the firm’s price target on Praxis Precision (PRAX) to $61 from $114 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision downgraded to Underperform from Neutral at Wedbush
- Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment
- H.C. Wainwright sees opportunity for quick rebound from Praxis after setback
- Dell reports mixed Q4 results, Intel delays Ohio chip factory: Morning Buzz
- Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position